Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | PDE8B | O95263 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL641090 | 1.00 | HSD17B10 (0.48) | HSD17B10LMNANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL25469908 | 1.00 | HSD17B10 (0.48) | HSD17B10LMNANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7986307 | 0.95 | PDE8B (0.47) | HSD17B10LMNANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL21597007 | 0.95 | PDE8B (0.47) | HSD17B10LMNANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5848588 | 0.90 | CTSK (0.41) | HSD17B10LMNANPSR1SMN1; SMN2CTSK | |
| SCHEMBL3141725 | 0.89 | HSD17B10 (0.49) | HSD17B10LMNANPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL3576321 | 0.85 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2ALDH1A1PDE8BNPC1 | |
| SCHEMBL135177 | 0.85 | L3MBTL1 (0.58) | HSD17B10SMN1; SMN2ALDH1A1PDE8BNPC1 | |
| SCHEMBL47049 | 0.85 | L3MBTL1 (0.58) | HSD17B10SMN1; SMN2ALDH1A1PDE8BNPC1 | |
| SCHEMBL133363 | 0.85 | L3MBTL1 (0.58) | HSD17B10SMN1; SMN2ALDH1A1PDE8BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12324802-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| US-20230357286-A1 | KETONE SYNTHESIS AND APPLICATIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-11-09 | — | — | US | disclosed |
| EP-4247817-A1 | MACROCYCLES CONTAINING A 1,3,4-OXADIAZOLE RING FOR USE AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-09-27 | — | — | EP | disclosed |
| CN-116670140-A | Macrocyclic compounds containing 1,3, 4-oxadiazole rings as modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20230099745-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2023-03-30 | — | — | US | disclosed |
| WO-2022109573-A1 | MACROCYCLES CONTAINING A 1,3,4-OXADIAZOLE RING FOR USE AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2020212351-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-10-22 | — | — | WO | disclosed |
| EP-3555094-A1 | BICYCLIC OGA INHIBITOR COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018154133-A1 | [1,2,4]-TRIAZOLO [1,5-A]-PYRIMIDINYL DERIVATIVES SUBSTITUTED WITH PIPERIDINE, MORPHOLINE OR PIPERAZINE AS OGA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-30 | — | — | WO | disclosed |
| WO-2018109198-A1 | BICYCLIC OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-21 | — | — | WO | disclosed |
| WO-2008084005-A1 | SPIROPIPERIDINE GLYCINAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-07-17 | — | — | WO | disclosed |
| US-7101896-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050267111-A1 | Pharmaceutical compositions and methods for use | DULL GARY M | 2005-12-01 | — | — | US | disclosed |
| US-6890935-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2005-05-10 | — | — | US | disclosed |
| WO-2004009599-A1 | FIVE-MEMBERED HETEROAROMATIC OLEFINIC AZACYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NCOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| WO-2002088114-A2 | HETEROARYL OFEFINIC AZACYCLIC AND HETEROARYL ACETYLENIC AZACYCLIC COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | TARGACEPT, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| US-20020160998-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-10-31 | — | — | US | disclosed |
| EP-1225955-A1 | ARYL OLEFINIC AZACYCLIC, AND ARYL ACETYLENIC AZACYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-05-16 | — | — | US | disclosed |
| WO-2001032264-A1 | ARYL OLEFINIC AZACYCLIC, AND ARYL ACETYLENIC AZACYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NICOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267111-A1 | Pharmaceutical compositions and methods for use | CYP3A7, AADAC, CYP2B6 | HSD17B10 624/4885LMNA 1971/4885NPSR1 1025/4885 |
| US-20020058652-A1 | Pharmaceutical compositions and methods for use | CYP3A7, AADAC, CYP2B6 | HSD17B10 624/4885LMNA 1971/4885NPSR1 1025/4885 |
| US-20020160998-A1 | Pharmaceutical compositions and methods for use | AADAC, CYP3A7, CYP3A5 | HSD17B10 483/4885LMNA 3252/4885NPSR1 810/4885 |
| US-20230357286-A1 | KETONE SYNTHESIS AND APPLICATIONS | NISCH, COASY, KLK7 | HSD17B10 81/4885LMNA 3202/4885NPSR1 3286/4885 |
| US-12324802-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1G, SCNN1B | HSD17B10 2742/4885LMNA 4099/4885NPSR1 3829/4885 |
| US-20230099745-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | HSD17B10 2742/4885LMNA 4099/4885NPSR1 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.